Cargando…
Developing Therapies for Peanut Allergy
Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not fe...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548240/ https://www.ncbi.nlm.nih.gov/pubmed/25531161 http://dx.doi.org/10.1159/000369340 |
_version_ | 1783255805991059456 |
---|---|
author | Bublin, Merima Breiteneder, Heimo |
author_facet | Bublin, Merima Breiteneder, Heimo |
author_sort | Bublin, Merima |
collection | PubMed |
description | Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not feasible due to the high risk of severe systemic side effects. The allergen-specific approaches under preclinical and clinical investigation comprise subcutaneous, oral, sublingual and epicutaneous immunotherapy with whole-peanut extracts as well as applications of hypoallergenic peanut allergens or T cell epitope peptides. Allergen-nonspecific approaches include monoclonal anti-IgE antibodies, TCM herbal formulations and Toll-like receptor 9-based immunotherapy. The potential of genetically engineered plants with reduced allergen levels is being explored as well as the beneficial influence of lactic acid bacteria and soybean isoflavones on peanut allergen-induced symptoms. Although the underlying mechanisms still need to be elucidated, several of these strategies hold great promise. It can be estimated that individual strategies or a combination thereof will result in a successful immunotherapy regime for peanut-allergic individuals within the next decade. |
format | Online Article Text |
id | pubmed-5548240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-55482402017-08-08 Developing Therapies for Peanut Allergy Bublin, Merima Breiteneder, Heimo Int Arch Allergy Immunol Article Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not feasible due to the high risk of severe systemic side effects. The allergen-specific approaches under preclinical and clinical investigation comprise subcutaneous, oral, sublingual and epicutaneous immunotherapy with whole-peanut extracts as well as applications of hypoallergenic peanut allergens or T cell epitope peptides. Allergen-nonspecific approaches include monoclonal anti-IgE antibodies, TCM herbal formulations and Toll-like receptor 9-based immunotherapy. The potential of genetically engineered plants with reduced allergen levels is being explored as well as the beneficial influence of lactic acid bacteria and soybean isoflavones on peanut allergen-induced symptoms. Although the underlying mechanisms still need to be elucidated, several of these strategies hold great promise. It can be estimated that individual strategies or a combination thereof will result in a successful immunotherapy regime for peanut-allergic individuals within the next decade. 2014-12-20 2014 /pmc/articles/PMC5548240/ /pubmed/25531161 http://dx.doi.org/10.1159/000369340 Text en http://creativecommons.org/licenses/by/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Bublin, Merima Breiteneder, Heimo Developing Therapies for Peanut Allergy |
title | Developing Therapies for Peanut Allergy |
title_full | Developing Therapies for Peanut Allergy |
title_fullStr | Developing Therapies for Peanut Allergy |
title_full_unstemmed | Developing Therapies for Peanut Allergy |
title_short | Developing Therapies for Peanut Allergy |
title_sort | developing therapies for peanut allergy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548240/ https://www.ncbi.nlm.nih.gov/pubmed/25531161 http://dx.doi.org/10.1159/000369340 |
work_keys_str_mv | AT bublinmerima developingtherapiesforpeanutallergy AT breitenederheimo developingtherapiesforpeanutallergy |